Fibrocell Science Stock Price, News & Analysis (NASDAQ:FCSC)

$0.66 0.00 (0.00 %)
(As of 02/19/2018 02:54 PM ET)
Previous Close$0.67
Today's Range$0.65 - $0.68
52-Week Range$0.61 - $4.64
Volume118,800 shs
Average Volume809,058 shs
Market Capitalization$15 million
P/E Ratio-0.37
Dividend YieldN/A
Beta0.43

About Fibrocell Science (NASDAQ:FCSC)

Fibrocell Science logoFibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Receive FCSC News and Ratings via Email

Sign-up to receive the latest news and ratings for FCSC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:FCSC
CUSIPN/A
Phone+1-484-7136000

Debt

Debt-to-Equity RatioN/A
Current Ratio3.52%
Quick Ratio3.52%

Price-To-Earnings

Trailing P/E Ratio-0.367582417582418
Forward P/E Ratio-0.40
P/E GrowthN/A

Sales & Book Value

Annual Sales$350,000.00
Price / Sales48.84
Cash FlowN/A
Price / CashN/A
Book Value$0.54 per share
Price / Book1.22

Profitability

Trailing EPS($1.82)
Net Income$-15,290,000.00
Net MarginsN/A
Return on Equity-640.52%
Return on Assets-100.12%

Miscellaneous

Employees23
Outstanding Shares25,900,000

Fibrocell Science (NASDAQ:FCSC) Frequently Asked Questions

What is Fibrocell Science's stock symbol?

Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC."

How were Fibrocell Science's earnings last quarter?

Fibrocell Science Inc (NASDAQ:FCSC) issued its earnings results on Thursday, November, 3rd. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.10. The company earned $0.22 million during the quarter, compared to analyst estimates of $0.07 million. View Fibrocell Science's Earnings History.

When will Fibrocell Science make its next earnings announcement?

Fibrocell Science is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Fibrocell Science.

Where is Fibrocell Science's stock going? Where will Fibrocell Science's stock price be in 2018?

3 brokers have issued 1 year price targets for Fibrocell Science's shares. Their predictions range from $2.00 to $7.00. On average, they expect Fibrocell Science's share price to reach $5.00 in the next year. View Analyst Ratings for Fibrocell Science.

Who are some of Fibrocell Science's key competitors?

Who are Fibrocell Science's key executives?

Fibrocell Science's management team includes the folowing people:

  • Douglas J. Swirsky, Chairman of the Board (Age 48)
  • John M. Maslowski, President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer (Age 42)
  • Lisa A. Embon, Vice President - of Corporate Accounting , Controller
  • Kelvin Moore, Lead Independent Director (Age 66)
  • Julian P. Kirk, Director (Age 42)
  • Marcus E. Smith, Director (Age 60)
  • Marc B. Mazur, Independent Director (Age 56)
  • Christine Thompson St.Clare, Independent Director (Age 66)

Who owns Fibrocell Science stock?

Fibrocell Science's stock is owned by a variety of of retail and institutional investors. Top institutional investors include KIRK RANDAL J (43.70%), Third Security LLC (31.92%), Sabby Management LLC (4.36%), Armistice Capital LLC (2.37%), Anson Funds Management LP (1.73%) and FNY Partners Fund LP (0.77%). Company insiders that own Fibrocell Science stock include David Pernock and Randal J Kirk. View Institutional Ownership Trends for Fibrocell Science.

Who bought Fibrocell Science stock? Who is buying Fibrocell Science stock?

Fibrocell Science's stock was bought by a variety of institutional investors in the last quarter, including Third Security LLC, Sabby Management LLC, Armistice Capital LLC, Anson Funds Management LP and FNY Partners Fund LP. Company insiders that have bought Fibrocell Science stock in the last two years include David Pernock and Randal J Kirk. View Insider Buying and Selling for Fibrocell Science.

How do I buy Fibrocell Science stock?

Shares of Fibrocell Science can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fibrocell Science's stock price today?

One share of Fibrocell Science stock can currently be purchased for approximately $0.66.

How big of a company is Fibrocell Science?

Fibrocell Science has a market capitalization of $15 million and generates $350,000.00 in revenue each year. The company earns $-15,290,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. Fibrocell Science employs 23 workers across the globe.

How can I contact Fibrocell Science?

Fibrocell Science's mailing address is 405 Eagleview Blvd, EXTON, PA 19341-1117, United States. The company can be reached via phone at +1-484-7136000 or via email at [email protected]


MarketBeat Community Rating for Fibrocell Science (FCSC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about Fibrocell Science and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Fibrocell Science (NASDAQ:FCSC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.00$5.53$4.00
Price Target Upside: 646.27% upside566.67% upside83.22% upside19.40% upside

Fibrocell Science (NASDAQ:FCSC) Consensus Price Target History

Price Target History for Fibrocell Science (NASDAQ:FCSC)

Fibrocell Science (NASDAQ:FCSC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/30/2018HC WainwrightSet Price TargetBuy$6.00HighView Rating Details
9/11/2017Canaccord GenuityReiterated RatingBuy$3.00 -> $7.00LowView Rating Details
3/7/2017Rodman & RenshawInitiated CoverageBuy -> Buy$2.00N/AView Rating Details
7/6/2016Griffin SecuritiesReiterated RatingBuy$12.00N/AView Rating Details
6/8/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
6/8/2016WedbushReiterated RatingNeutral$1.50 -> $4.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Fibrocell Science (NASDAQ:FCSC) Earnings History and Estimates Chart

Earnings by Quarter for Fibrocell Science (NASDAQ:FCSC)

Fibrocell Science (NASDAQ FCSC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.35)N/AView Earnings Details
11/13/2017Q3 2017($0.41)($0.34)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.31)($0.31)ViewListenView Earnings Details
5/10/2017Q1 2017($0.29)($0.58)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.81)($0.33)$0.02 million$0.04 millionViewN/AView Earnings Details
11/3/2016Q316($0.15)($0.05)$0.07 million$0.22 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.39)($0.42)$0.04 million$0.09 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.48)$0.12$0.07 million$0.02 millionViewN/AView Earnings Details
3/10/2016Q415($0.17)($0.40)$0.07 million$0.08 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.07)$0.06 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q215($0.16)($0.17)$0.09 million$0.14 millionViewN/AView Earnings Details
5/8/2015Q1 2015($0.16)($0.17)$0.05 million$0.19 millionViewN/AView Earnings Details
3/13/2015Q4 2014($0.16)($0.16)$0.06 million$0.06 millionViewN/AView Earnings Details
11/7/2014Q3 14($0.14)($0.17)$0.06 million$0.02 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.18)($0.08)$0.07 million$0.06 millionViewN/AView Earnings Details
5/19/2014Q114($0.15)($0.35)$0.05 million$0.05 millionViewN/AView Earnings Details
3/17/2014Q414($0.26)($0.14)$0.05 million$0.04 millionViewN/AView Earnings Details
11/14/2013Q3 2013($0.63)($1.44)$0.07 million$0.07 millionViewN/AView Earnings Details
5/15/2013Q1 2013($0.66)$0.03 millionViewN/AView Earnings Details
11/17/2011Q3 2011($4.50)($1.35)ViewN/AView Earnings Details
8/15/2011Q2 2011($23.85)ViewN/AView Earnings Details
5/18/2011Q1 2011($9.75)($14.33)ViewN/AView Earnings Details
11/18/2010Q3 2010($6.98)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Fibrocell Science (NASDAQ:FCSC) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.26)($0.26)($0.26)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.23)($0.23)($0.23)
Q4 20181($0.23)($0.23)($0.23)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Fibrocell Science (NASDAQ:FCSC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Fibrocell Science (NASDAQ FCSC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 40.97%
Insider Trades by Quarter for Fibrocell Science (NASDAQ:FCSC)
Institutional Ownership by Quarter for Fibrocell Science (NASDAQ:FCSC)

Fibrocell Science (NASDAQ FCSC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/11/2017Randal J KirkMajor ShareholderBuy2,727,273$0.77$2,100,000.21View SEC Filing  
12/2/2016David PernockChairmanBuy50,000$0.92$46,000.00105,600View SEC Filing  
11/13/2015David PernockCEOBuy3,000$5.00$15,000.0055,600View SEC Filing  
8/11/2015David PernockCEOBuy3,500$6.54$22,890.00View SEC Filing  
7/27/2015Randal J KirkMajor ShareholderBuy975,987$5.80$5,660,724.60View SEC Filing  
5/13/2015David PernockCEOBuy16,600$4.30$71,380.00View SEC Filing  
12/12/2014David PernockCEOBuy5,000$2.52$12,600.00View SEC Filing  
11/20/2014David PernockCEOBuy5,000$2.54$12,700.00View SEC Filing  
11/20/2014John Michael MaslowskiVPBuy1,000$2.54$2,540.00View SEC Filing  
6/5/2014Christine St.ClareDirectorBuy10,000$3.00$30,000.00View SEC Filing  
6/5/2014David PernockCEOBuy12,500$2.95$36,875.00View SEC Filing  
6/4/2014Kelvin MooreDirectorBuy4,557$2.99$13,625.43View SEC Filing  
6/4/2014Randal J KirkMajor ShareholderBuy400,000$2.90$1,160,000.00View SEC Filing  
1/24/2014Randal J KirkMajor ShareholderBuy1,024,590$4.88$4,999,999.20View SEC Filing  
11/21/2013David PernockCEOBuy10,000$3.69$36,900.00View SEC Filing  
11/20/2013Gregory L WeaverCFOBuy10,000$3.51$35,100.00View SEC Filing  
10/1/2013Randal J KirkMajor ShareholderBuy3,658,536$4.10$14,999,997.60View SEC Filing  
7/26/2013Randal J KirkMajor ShareholderBuy1,243,781$6.03$7,499,999.43View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Fibrocell Science (NASDAQ FCSC) News Headlines

Source:
DateHeadline
Comparing Organovo (ONVO) & Fibrocell Science (FCSC)Comparing Organovo (ONVO) & Fibrocell Science (FCSC)
www.americanbankingnews.com - February 17 at 12:26 PM
Fibrocell Science (FCSC) Rating Lowered to Hold at Zacks Investment ResearchFibrocell Science (FCSC) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 14 at 11:42 PM
Zacks Investment Research Upgrades Fibrocell Science (FCSC) to BuyZacks Investment Research Upgrades Fibrocell Science (FCSC) to Buy
www.americanbankingnews.com - February 14 at 12:28 AM
Zacks: Brokerages Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per ShareZacks: Brokerages Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - February 7 at 11:16 AM
Fibrocell Science (FCSC) Lowered to "Hold" at Zacks Investment ResearchFibrocell Science (FCSC) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 6 at 11:06 PM
Fibrocell to Present at 20th Annual BIO CEO & Investor ConferenceFibrocell to Present at 20th Annual BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:28 AM
Fibrocell Science (FCSC) Lifted to "Buy" at Zacks Investment ResearchFibrocell Science (FCSC) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - February 5 at 11:24 PM
BRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin DisorderBRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder
www.reuters.com - February 5 at 9:34 AM
Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized SclerodermaFibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
finance.yahoo.com - February 5 at 9:34 AM
Wired News – Fibrocell Science Gets FDA Allowance to Start Pediatric Enrollment in Phase-1/2 Clinical Trial of FCX-007 for the Treatment of RDEBWired News – Fibrocell Science Gets FDA Allowance to Start Pediatric Enrollment in Phase-1/2 Clinical Trial of FCX-007 for the Treatment of RDEB
finance.yahoo.com - February 1 at 9:40 AM
Fibrocell Science (FCSC) PT Set at $6.00 by HC WainwrightFibrocell Science (FCSC) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - January 30 at 8:02 PM
Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
finance.yahoo.com - January 30 at 9:22 AM
Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018 Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018 
finance.yahoo.com - January 24 at 8:06 AM
Fibrocell Science Inc (NASDAQ:FCSC) And The Healthcare Sector Outlook 2018Fibrocell Science Inc (NASDAQ:FCSC) And The Healthcare Sector Outlook 2018
finance.yahoo.com - January 24 at 8:06 AM
Fibrocell Science Inc (FCSC) Expected to Post Earnings of -$0.23 Per ShareFibrocell Science Inc (FCSC) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - January 21 at 1:08 PM
Fibrocell Science (FCSC) Upgraded to "Buy" at Zacks Investment ResearchFibrocell Science (FCSC) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 19 at 12:12 AM
Zacks: Brokerages Anticipate Fibrocell Science Inc (FCSC) Will Announce Earnings of -$0.38 Per ShareZacks: Brokerages Anticipate Fibrocell Science Inc (FCSC) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - January 4 at 5:30 PM
Fibrocell Science Has New Capital in Hand, Updates Investors on Pipeline ProductsFibrocell Science Has New Capital in Hand, Updates Investors on Pipeline Products
finance.yahoo.com - January 4 at 9:38 AM
Why Fibrocell Science Inc’s (NASDAQ:FCSC) Investor Composition Impacts Your ReturnsWhy Fibrocell Science Inc’s (NASDAQ:FCSC) Investor Composition Impacts Your Returns
finance.yahoo.com - January 2 at 11:30 PM
Fibrocell Science Inc (FCSC) Short Interest Down 75.7% in DecemberFibrocell Science Inc (FCSC) Short Interest Down 75.7% in December
www.americanbankingnews.com - January 1 at 1:16 AM
BRIEF-Fibrocell Science Says Expects IND Filing Of FCX-013 In Q1 2018BRIEF-Fibrocell Science Says Expects IND Filing Of FCX-013 In Q1 2018
www.reuters.com - December 30 at 5:03 PM
 Brokerages Expect Fibrocell Science Inc (FCSC) to Post -$0.52 EPS Brokerages Expect Fibrocell Science Inc (FCSC) to Post -$0.52 EPS
www.americanbankingnews.com - December 19 at 3:14 AM
ETFs with exposure to Fibrocell Science, Inc. : December 14, 2017ETFs with exposure to Fibrocell Science, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:43 PM
Randal J. Kirk Buys 2,727,273 Shares of Fibrocell Science Inc (FCSC) StockRandal J. Kirk Buys 2,727,273 Shares of Fibrocell Science Inc (FCSC) Stock
www.americanbankingnews.com - December 13 at 8:58 PM
Chester County gene therapy company completes $10.5M stock saleChester County gene therapy company completes $10.5M stock sale
finance.yahoo.com - December 12 at 5:36 PM
Should You Worry About Fibrocell Science Inc’s (FCSC) CEO Pay Check?Should You Worry About Fibrocell Science Inc’s (FCSC) CEO Pay Check?
finance.yahoo.com - December 9 at 9:42 AM
Fibrocell Science Inc (FCSC) Feels the Heat of Share DilutionFibrocell Science Inc (FCSC) Feels the Heat of Share Dilution
finance.yahoo.com - December 7 at 5:35 PM
Fibrocell Announces Pricing of $10.5 Million Underwritten Public OfferingFibrocell Announces Pricing of $10.5 Million Underwritten Public Offering
finance.yahoo.com - December 7 at 9:57 AM
Was Fibrocell Science Inc’s (FCSC) Earnings Growth Better Than Industry?Was Fibrocell Science Inc’s (FCSC) Earnings Growth Better Than Industry?
finance.yahoo.com - November 30 at 10:08 AM
Short Interest in Fibrocell Science Inc (FCSC) Rises By 43.3%Short Interest in Fibrocell Science Inc (FCSC) Rises By 43.3%
www.americanbankingnews.com - November 29 at 2:08 AM
Head-To-Head Analysis: Fibrocell Science (FCSC) vs. Roka Bioscience (ROKA)Head-To-Head Analysis: Fibrocell Science (FCSC) vs. Roka Bioscience (ROKA)
www.americanbankingnews.com - November 27 at 3:18 AM
Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - November 14 at 7:00 PM
Fibrocell Sciences (FCSC) CEO John Maslowski on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaFibrocell Science's (FCSC) CEO John Maslowski on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 14 at 7:00 PM
Fibrocell Science Inc (FCSC) Issues Quarterly  Earnings ResultsFibrocell Science Inc (FCSC) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 13 at 11:30 AM
Fibrocell Science, Inc. to Host Earnings CallFibrocell Science, Inc. to Host Earnings Call
finance.yahoo.com - November 13 at 10:12 AM
Fibrocell Reports Third Quarter 2017 Financial Results and Recent HighlightsFibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - November 13 at 10:12 AM
Fibrocell Science reports 3Q lossFibrocell Science reports 3Q loss
finance.yahoo.com - November 13 at 10:12 AM
Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss - NasdaqIntrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss - Nasdaq
www.nasdaq.com - November 11 at 8:33 AM
Pre-Market Earnings Report for November 13, 2017 : JD, TSN, ACM, ABY, VRAY, KMDA, PTN, ASUR, RDHL, CYRN ... - NasdaqPre-Market Earnings Report for November 13, 2017 : JD, TSN, ACM, ABY, VRAY, KMDA, PTN, ASUR, RDHL, CYRN ... - Nasdaq
www.nasdaq.com - November 11 at 8:33 AM
Comparing Fibrocell Science (FCSC) & ANI Pharmaceuticals (ANIP)Comparing Fibrocell Science (FCSC) & ANI Pharmaceuticals (ANIP)
www.americanbankingnews.com - November 11 at 5:48 AM
Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues MissIntrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss
finance.yahoo.com - November 10 at 3:00 PM
New Skin for 7-Year-Old Boy Marks Advance in Gene TherapyNew Skin for 7-Year-Old Boy Marks Advance in Gene Therapy
finance.yahoo.com - November 9 at 3:15 AM
Fibrocell Science Inc (FCSC) Scheduled to Post Quarterly Earnings on MondayFibrocell Science Inc (FCSC) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 7 at 10:08 AM
Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 ... - GlobeNewswire (press release)Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 ... - GlobeNewswire (press release)
globenewswire.com - November 6 at 8:23 PM
Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational HighlightsFibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - November 6 at 8:23 PM
Whats in Store for Intrexon (XON) This Earnings Season? - NasdaqWhat's in Store for Intrexon (XON) This Earnings Season? - Nasdaq
www.nasdaq.com - October 31 at 7:48 PM
What's in Store for Intrexon (XON) This Earnings Season?What's in Store for Intrexon (XON) This Earnings Season?
finance.yahoo.com - October 31 at 7:48 PM
Reviewing NovaBay Pharmaceuticals (NBY) & Fibrocell Science (FCSC)Reviewing NovaBay Pharmaceuticals (NBY) & Fibrocell Science (FCSC)
www.americanbankingnews.com - October 20 at 6:46 AM
Fibrocell Science: A Very Appealing Gene Therapy Play - Seeking AlphaFibrocell Science: A Very Appealing Gene Therapy Play - Seeking Alpha
seekingalpha.com - October 19 at 7:21 PM
Fibrocell Science Inc (FCSC) Upgraded to Hold at Zacks Investment ResearchFibrocell Science Inc (FCSC) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 10 at 7:40 PM

SEC Filings

Fibrocell Science (NASDAQ:FCSC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Fibrocell Science (NASDAQ:FCSC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Fibrocell Science (NASDAQ FCSC) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.